Chardan Capital Has Positive Outlook of GANX FY2024 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities researchers at Chardan Capital increased their FY2024 earnings per share (EPS) estimates for Gain Therapeutics in a research report issued on Tuesday, November 19th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings per share of ($0.99) for the year, up from their prior forecast of ($1.01). Chardan Capital currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.04) per share. Chardan Capital also issued estimates for Gain Therapeutics’ FY2025 earnings at ($0.74) EPS.

A number of other equities research analysts have also issued reports on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, October 9th.

Gain Therapeutics Stock Performance

NASDAQ:GANX opened at $1.72 on Friday. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $5.33. The company has a market capitalization of $45.62 million, a P/E ratio of -1.56 and a beta of 0.33. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $2.06 and a two-hundred day moving average price of $1.73.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics in the second quarter valued at $66,000. Renaissance Technologies LLC grew its holdings in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the period. Hohimer Wealth Management LLC acquired a new position in shares of Gain Therapeutics during the 2nd quarter valued at about $422,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after acquiring an additional 88,236 shares during the period. 11.97% of the stock is currently owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.